Relay Therapeutics, Inc. (RLAY) has a consensus analyst rating of Buy, based on 15 analysts covering the stock. Of those, 15 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for RLAY is $16.33, representing a +10.7% upside from the current price of $14.75. Price targets range from a low of $13.00 to a high of $22.00.
